The role of hepatic resection in the treatment of hepatocellular cancer

Hepatology

Volumn 62, Issue 2, 2015, Pages 440-451

  Roayaie, Sasan ^a   Jibara, Ghalib ^b   Tabrizian, Parissa ^c   Park, Joong Won ^d   Yang, Jijin ^e   Yan, Lunan ^f   Schwartz, Myron ^c   Han, Guohong ^g   Izzo, Francesco ^h   Chen, Mishan ⁱ   Blanc, Jean Frédéric ^j   Johnson, Philip ^k   Kudo, Masatoshi ^l   Roberts, Lewis R ^m   Sherman, Morris ⁿ  

^a LENOX HILL HOSPITAL   (United States)

^b Brookdale Medical Center   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d National Cancer Center   (South Korea)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f SICHUAN UNIVERSITY   (China)

^g FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^j HÔPITAL SAINT ANDRÉ   (France)

^k UNIVERSITY OF LIVERPOOL   (United Kingdom)

^l KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m MAYO CLINIC   (United States)

ⁿ UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BILIRUBIN; DOXORUBICIN; ERLOTINIB; SORAFENIB;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOEMBOLIZATION; COHORT ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PORTAL HYPERTENSION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SURVIVAL RATE; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PATHOLOGY; PATIENT SELECTION; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; UNITED STATES;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84938211968     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27745     Document Type: Article

References (24)

1. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
2. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
3. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-1440.
4. Borzio M, Fornari F, De Sio I, Andriulli A, Terracciano F, Parisi G, et al. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. Future Oncol 2013;9:283-294.
5. Farinati F, Sergio A, Baldan A, Giacomin A, Di Nolfo MA, Del Poggio P, et al. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer 2009;9:33.
6. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC east-west study group. Ann Surg 2013;257:929-937.
7. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008;134:1908-1916.
8. Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Ramacciato G, et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg 2009;250:922-928.
9. Capussotti L, Ferrero A, Vigano L, Muratore A, Polastri R, Bouzari H. Portal hypertension: contraindication to liver surgery? World J Surg 2006;30:992-999.
10. Masuda T, Beppu T, Nakagawa S, Okabe H, Chikamoto A, Miyata T, et al. Assessment of safety in hepatic resection for hepatocellular carcinoma focusing on indirect hyperbilirubinemia. J Hepatobiliary Pancreat Sci 2013;20:370-374.
11. Giannini EG, Savarino V, Farinati F, Ciccarese F, Rapaccini G, Marco MD, et al. Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. Liver Int 2013;33:1594-1600.
12. Torzilli G, Donadon M, Marconi M, Palmisano A, Del Fabbro D, Spinelli A, et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the barcelona clinic liver cancer classification: results of a prospective analysis. Arch Surg 2008;143:1082-1090.
13. Kuroda S, Tashiro H, Kobayashi T, Oshita A, Amano H, Ohdan H. Selection criteria for hepatectomy in patients with hepatocellular carcinoma classified as Child-Pugh class B. World J Surg 2011;35:834-841.
14. Kobayashi T, Itamoto T, Tashiro H, Amano H, Oshita A, Tanimoto Y, et al. Tumor-related factors do not influence the prognosis of solitary hepatocellular carcinoma after partial hepatectomy. J Hepatobiliary Pancreat Sci 2011;18:689-699.
15. Iranmanesh P, Vazquez O, Terraz S, Majno P, Spahr L, Poncet A, et al. Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma. J Hepatol 2014;60:969-974.
16. Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology 2015;61:526-536.
17. Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the milan criteria. Ann Surg 2010;252:903-912.
18. Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012;57:794-802.
19. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-328.
20. Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013;58:724-729.
21. Choi SH, Choi GH, Kim SU, Park JY, Joo DJ, Ju MK, et al. Role of surgical resection for multiple hepatocellular carcinomas. World J Gastroenterol 2013;19:366-374.
22. Zhong JH, Xiang BD, Gong WF, Ke Y, Mo QG, Ma L, et al. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One 2013;8:e68193.
23. Peng ZW, Guo RP, Zhang YJ, Lin XJ, Chen MS, Lau WY. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer 2012;118:4725-4736.
24. Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol 2014;61:82-88.